Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 4
  • Print publication year: 2011
  • Online publication date: August 2011

3 - Evidence-based treatment

Related content

Powered by UNSILO


1. HenningsenP, ZipfelS, HerzogW.Management of functional somatic syndromes. The Lancet 2007; 369(9565): 946–55.
2. RuddyR, HouseA. Psychosocial interventions for conversion disorder. Cochrane Database of Systematic Reviews 2005; 4: CD005331.
3. KroenkeK. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosomatic Medicine 2007; 69(9): 881–8.
4. GoldbergD, GaskL, OdowdT. The treatment of somatization – teaching techniques of reattribution. Journal of Psychosomatic Research 1989; 33(6): 689–95.
5. GaskL, GoldbergD, PorterR, CreedF. The treatment of somatization – evaluation of a teaching package with general-practice trainees. Journal of Psychosomatic Research 1989; 33(6): 697–703.
6. van der Feltz Cornelis, Van OsTW, HarmWJ, Van MarwijkHW, LeentjensAF. Effect of psychiatric consultation models in primary care. A systematic review and meta-analysis of randomised controlled trials. Journal of Psychosomatic Research 2010; 68: 521–33.
7. RaineR, HainesA, SenskyT, HutchingsA, LarkinK, BlackN. Systematic review of mental health interventions for patients with common somatic symptoms: can research evidence from secondary care be extrapolated to primary care?British Medical Journal 2002; 325(7372): 1082.
8. AllenLA, WoolfolkRL, EscobarJI, GaraMA, HamerRM, AllenLAet al. Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial. Archives of Internal Medicine 2006; 166(14): 1512–18.
9. KashnerTM, RostK, CohenB, AndersonM, SmithGR. Enhancing the health of somatization disorder patients – effectiveness of short-term group-therapy. Psychosomatics 1995; 36(5): 462–70.
10. HuibersMJ, BeurskensAJ, BleijenbergG, van SchayckCP. The effectiveness of psychosocial interventions delivered by general practitioners. Cochrane Database of Systematic Reviews 2003; 2: CD003494.
11. BlankensteinAH, van der HorstHE, SchilteAF, de VriesD, ZaatJO, AndreKJet al. Development and feasibility of a modified reattribution model for somatising patients, applied by their own general practitioners. Patient Education and Counseling 2002; 47(3): 229–35.
12. LidbeckJ. Group therapy for somatization disorders in general practice: Effectiveness of a short cognitive-behavioural treatment model. Acta Psychiatrica Scandinavica 1997; 96(1): 14–24.
13. LarischA, SchweickhardtA, WirschingM, FritzscheK. Psychosocial interventions for somatizing patients by the general practitioner – A randomized controlled trial. Journal of Psychosomatic Research 2004; 57(6): 507–14.
14. VolzHP, MollerHJ, ReimannI, StollKD. Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial. European Neuropsychopharmacology 2000; 10(3): 211–17.
15. VolzHP, MurckH, KasperS, MollerHJ. St John’s wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology 2002; 164(3): 294–300.
16. KroenkeK, MessinaN, BenattiaI, GraepelJ, MusgnungJ. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. Journal of Clinical Psychiatry 2006; 67(1): 72–80.
17. MorrissR, DowrickC, SalmonP, PetersS, DunnG, RogersAet al. Cluster randomised controlled trial of training practices in reattribution for medically unexplained symptoms. British Journal of Psychiatry 2007; 191: 536–42.
18. EscobarJI, GaraMA, az-MartinezAM, InterianA, WarmanM, AllenLAet al. Effectiveness of a time-limited cognitive behavior therapy – type intervention among primary care patients with medically unexplained symptoms. Annals of Family Medicine 2007; 5: 328–35.
19. SumathipalaA, SiribaddanaS, AbeysinghaMR, De SilvaP, DeweyM, PrinceMet al. Cognitive-behavioural therapy v. structured care for medically unexplained symptoms: randomised controlled trial. British Journal of Psychiatry 2008; 193(1): 51–9.
20. AiarzaguenaJM, GrandesG, GamindeI, SalazarA, SanchezA, ArinoJ. A randomized controlled clinical trial of a psychosocial and communication intervention carried out by GPs for patients with medically unexplained symptoms. Psychological Medicine 2007; 37(2): 283–94.
21. ToftT, RosendalM, ØrnbølE, OlesenF, FrostholmL, FinkP. Training general practitioners in the treatment of functional somatic symptoms: effects on patient health in a cluster-randomised controlled trial (the functional illness in primary care study). Psychotherapy and Psychosomatics 2010; 79(4): 227–37.
22. SalmonP, PetersS, StanleyI. Patients’ perceptions of medical explanations for somatisation disorders: qualitative analysis. British Medical Journal 1999; 318(7180): 372–6.
23. ThomasKB. General-practice consultations – is there any point in being positive. British Medical Journal 1987; 294(6581): 1200–2.
24. MorrissRK, GaskL, RonaldsC, Downes-GraingerE, ThompsonH, GoldbergD. Clinical and patient satisfaction outcomes of a new treatment for somatized mental disorder taught to general practitioners. British Journal of General Practice 1999; 49(441): 263–7.
25. RosendalM, BroF, FinkP, ChristensenKS, OlesenF, RosendalMet al. Diagnosis of somatisation: effect of an educational intervention in a cluster randomised controlled trial. British Journal of General Practice 2003; 53(497): 917–22.
26. GaskL. Personal communication, 2011.
27. van der Feltz-CornelisCM, van OppenP, AderHJ, van DyckR, van der Feltz-CornelisC, van OppenPet al. Randomised controlled trial of a collaborative care model with psychiatric consultation for persistent medically unexplained symptoms in general practice. Psychotherapy and Psychosomatics 2006; 75(5): 282–9.
28. SmithRC, GardinerJC, LuoZH, SchooleyS, LameratoL, RostK. Primary care physicians treat somatization. Journal of General Internal Medicine 2009; 24(7): 829–32.
29. SmithRC, GardinerJC, LylesJS, SirbuC, DwamenaFC, HodgesAet al. Exploration of DSM-IV criteria in primary care patients with medically unexplained symptoms. Psychosomatic Medicine 2005; 67(1): 123–9.
30. SmithRC, LylesJS, GardinerJC, SirbuC, HodgesA, CollinsCet al. Primary care clinicians treat patients with medically unexplained symptoms: A randomized controlled trial. Journal of General Internal Medicine 2006; 21(7): 671–7.
31. RosendalM, OlesenF, FinkP. Management of medically unexplained symptoms. British Medical Journal 2005; 330(7481): 4–5.
32. SalmonP, DowrickCF, RingA, HumphrisGM. Voiced but unheard agendas: qualitative analysis of the psychosocial cues that patients with unexplained symptoms present to general practitioners. British Journal of General Practice 2004; 54(500): 171–6.
33. SalmonP, HumphrisGM, RingA, DaviesJC, DowrickCF. Why do primary care physicians propose medical care to patients with medically unexplained symptoms? A new method of sequence analysis to test theories of patient pressure. Psychosomatic Medicine 2006; 68(4): 570–7.
34. SalmonP, HumphrisGM, RingA, DaviesJC, DowrickCF. Primary care consultations about medically unexplained symptoms: patient presentations and doctor responses that influence the probability of somatic intervention. Psychosomatic Medicine 2007; 69(6): 571–7.
35. EpsteinRM, HadeeT, CarrollJ, MeldrumSC, LardnerJ, ShieldsCG. ‘Could this be something serious?’ – Reassurance, uncertainty, and empathy in response to patients’ expressions of worry. Journal of General Internal Medicine 2007; 22(12): 1731–9.
36. van DulmenAM, FennisJF, MokkinkHG, van der VeldenHG, BleijenbergG. Doctor-dependent changes in complaint-related cognitions and anxiety during medical consultations in functional abdominal complaints. Psychological Medicine 1995; 25(5): 1011–18.
37. McDonaldIG, DalyJ, JelinekVM, PanettaF, GutmanJM. Opening Pandora’s box: The unpredictability of reassurance by a normal test result. British Medical Journal 1996; 313(7053): 329–32.
38. StephensonDT, PriceJR. Medically unexplained physical symptoms in emergency medicine. Emergency Medicine Journal 2006; 23(8): 595–600.
39. LucockMP, MorleyS, WhiteC, PeakeMD. Responses of consecutive patients to reassurance after gastroscopy: results of self administered questionnaire survey. British Medical Journal 1997; 315(7108): 572–5.
40. HowardLM, WesselyS. Reappraising reassurance – The role of investigations. Journal of Psychosomatic Research 1996; 41(4): 307–11.
41. DowrickCFR. Normalisation of unexplained symptoms by general practitioners: a functional typology. British Journal of General Practice 2004; 54(500): 165–70.
42. PetrieKJ, MullerJT, SchirmbeckF, DonkinL, BroadbentE, EllisCJet al. Effect of providing information about normal test results on patients’ reassurance: randomised controlled trial. British Medical Journal 2007; 334(7589): 352–4.
43. ThomsonAB, PageLA. Psychotherapies for hypochondriasis. Cochrane Database of Systematic Reviews 2007; 4: CD006520.
44. BarskyAJ, AhernDK. Cognitive behavior therapy for hypochondriasis: a randomized controlled trial. Journal of the American Medical Association 2004; 291(12): 1464–70.
45. SumathipalaA. What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies. Psychosomatic Medicine 2007; 69(9): 889–900.
46. KroenkeK, SwindleR. Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychotherapy and Psychosomatics 2000; 69(4): 205–15.
47. O’MalleyPG, JacksonJL, SantoroJ, TomkinsG, BaldenE, KroenkeK. Antidepressant therapy for unexplained symptoms and symptom syndromes. Journal of Family Practice 1999; 48(12): 980–90.
48. JacksonJL, O’MalleyPG, KroenkeK. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectrums 2006; 11(3): 212–22.
49. MojaPL, CusiC, SterziRR, CanepariC. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database of Systematic Reviews 2005; 3: CD002919.
50. RainsJC, PenzienDB, McCroryDC, GrayRN. Behavioral headache treatment: History, review of the empirical literature, and methodological critique. Headache 2005; 45: S92–S109.
51. AbbassA, KiselyS, KroenkeK. Short-term psychodynamic psychotherapy for somatic disorders systematic review and meta-analysis of clinical trials. Psychotherapy and Psychosomatics 2009; 78(5): 265–74.
52. SmeetsRJEM, VlaeyenJWS, KesterAD, KnottnerusJA.Reduction of pain catastrophizing mediates the outcome of both physical and cognitive-behavioral treatment in chronic low back pain. Journal of Pain 2006; 7(4): 261–71.
53. SpinhovenP, ter KuileM, Kole-SnijdersAMJ, MansfeldMH, den OudenDJ, VlaeyenJWS. Catastrophizing and internal pain control as mediators of outcome in the multidisciplinary treatment of chronic low back pain. European Journal of Pain 2004; 8(3): 211–19.
54. BuschAJ, BarberKAR, OverendTJ, PelosoPMJ, SchachterCL. Exercise for treating fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2007; 4: CD003786.
55. StaudR. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthritis Research and Therapy 2006; 8(3): 208.
56. van WeeringM, Vollenbroek-HuttenMMR, KotteEM, HermensHJ. Daily physical activities of patients with chronic pain or fatigue versus asymptomatic controls. A systematic review. Clinical Rehabilitation 2007; 21(11): 1007–23.
57. ClarkLV, WhitePD. The role of deconditioning and therapeutic exercise in chronic fatigue syndrome. Journal of Mental Health 2005; 14: 237–52.
58. PrinsJB, BazelmansE, van der WerfS, van der MeerJWM, BleijenbergG. Cognitive behaviour therapy for chronic fatigue syndrome: predictors of treatment outcome. Psycho-Neuro-Endocrino-Immunology 2002; 1241: 131–5.
59. WhitePD. What causes chronic fatigue syndromes? British Medical Journal 2004; 329(7472): 928–9.
60. van HoudenhoveB, LuytenP. Customizing treatment of chronic fatigue syndrome and fibromyalgia: the role of perpetuating factors. Psychosomatics 2008; 49(6): 470–7.
61. SurawyC, HackmannA, HawtonK, SharpeM. Chronic fatigue syndrome – a cognitive approach. Behaviour Research and Therapy 1995; 33(5): 535–44.
62. VercoulenJH, BazelmansE, SwaninkCM, FennisJF, GalamaJM, JongenPJet al. Physical activity in chronic fatigue syndrome: assessment and its role in fatigue. Journal of Psychiatric Research 1997; 31(6): 661–73.
63. LangeM, PetermannF. Influence of depression on fibromyalgia. A systematic review. Schmerz 2010; 24(4): 326–33.
64. CreedF, RatcliffeJ, FernandesL, PalmerS, RigbyC, TomensonBet al. Outcome in severe irritable bowel syndrome with and without accompanying depressive, panic and neurasthenic disorders. British Journal of Psychiatry 2005; 186: 507–15.
65. GuthrieE, CreedF, DawsonD, TomensonB. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991; 100: 450–7.
66. GuthrieE. Brief psychotherapy with patients with refractory irritable bowel syndrome. British Journal of Psychotherapy 1991; 8: 175–88.
67. National Institute for Health and Clinical Excellence. Irritable Bowel Syndrome in Adults. Diagnosis and Management of Irritable Bowel Syndrome in Primary Care. London: NICE; 2008.
68. FordAC, TalleyNJ, SchoenfeldPS, QuigleyEMM, MoayyediP. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58(3): 367–78.
69. HauserW, BernardyK, UceylerN, SommerC. Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. Journal of the American Medical Association 2009; 301(2): 198–209.
70. CreedF. How do SSRIs help patients with irritable bowel syndrome?Gut 2006; 55(8): 1065–7.
71. SpillerR, AzizQ, CreedF, EmmanuelA, HoughtonL, HunginPet al. Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56(12): 1770–98.
72. PaivaES, JonesKD. Rational treatment of fibromyalgia for a solo practitioner. Best Practice and Research: Clinical Rheumatology 2010; 24(3): 341–52.
73. CarvilleSF, rendt-NielsenS, BliddalH, BlotmanF, BrancoJC, BuskilaDet al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Annals of the Rheumatic Diseases 2008; 67(4): 536–41.
74. National Institute for Health and Clinical Excellence. Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Diagnosis and Management of CFS/ME in Adults and Children. London: NICE; 2007.
75. ArnoldLM, ClauwD, WangF, AhlJ, GaynorPJ, WohlreichMM. Flexible dosed duloxetine in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled trial. Journal of Rheumatology 2010; 37(12): 2578–86.
76. ArnoldLM. Strategies for managing fibromyalgia. American Journal of Medicine 2009; 122(Suppl 12): S31–S43.
77. AaronLA, HerrellR, AshtonS, BelcourtM, SchmalingK, GoldbergJet al. Comorbid clinical conditions in chronic fatigue: a co-twin control study. Journal of General Internal Medicine 2001; 16(1): 24–31.
78. HenningsenP, ZimmermannP. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosomatic Medicine 2003; 65(4): 528–33.
79. ChambersD, BagnallAM, HempelS, ForbesC, ChambersD, BagnallAMet al. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. Journal of the Royal Society of Medicine 2006; 99(10): 506–20.
80. EdmondsM, McGuireH, PriceJ. Exercise therapy for chronic fatigue syndrome. Cochrane Database of Systematic Reviews 2004; 3: CD003200.
81. MalouffJM, ThorsteinssonEB, SchutteNS. The efficacy of problem solving therapy in reducing mental and physical health problems: A meta-analysis. Clinical Psychology Review 2007; 27(1): 46–57.
82. PriceJR, CouperJ. Cognitive behaviour therapy for adults with chronic fatigue syndrome. Cochrane Database of Systematic Reviews 2000; 2: CD001027.
83. O’DowdH, GladwellP, RogersCA, HollinghurstS, GregoryA, O’DowdHet al. Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme. Health Technology Assessment 2006; 10(37): 1–121.
84. KnoopH, BleijenbergG, GielissenMFM, van der MeerJWM, WhitePD. Is a full recovery possible after cognitive behavioural therapy for chronic fatigue syndrome?Psychotherapy and Psychosomatics 2007; 76(3): 171–6.
85. DealeA, HusainK, ChalderT, WesselyS. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. American Journal of Psychiatry 2001; 158(12): 2038–42.
86. PowellP, BentallRP, NyeFJ, EdwardsRHT. Patient education to encourage graded exercise in chronic fatigue syndrome – 2-year follow-up of randomised control led trial. British Journal of Psychiatry 2004; 184: 142–6.
87. StulemeijerM, De JongLWAM, FiselierTJW, HoogveldSWB, BleijenbergG. Cognitive behaviour therapy for adolescents with chronic fatigue syndrome: randomised controlled trial. British Medical Journal 2005; 330(7481): 14–17.
88. KnoopH, StulemeijerM, De JongLWAM, FiselierTJW, BleijenbergG. Efficacy of cognitive behavioral therapy for adolescents with chronic fatigue syndrome: Long-term follow-up of a randomized, controlled trial. Pediatrics 2008; 121(3): E619–E25.
89. ChalderT, DearyV, HusainK, WalwynR. Family-focused cognitive behaviour therapy versus psycho-education for chronic fatigue syndrome in 11- to 18-year-olds: a randomized controlled treatment trial. Psychological Medicine 2010; 40(8): 1269–79.
90. HeinsMJ, KnoopH, PrinsJB, StulemeijerM, van der MeerJWM, BleijenbergG. Possible detrimental effects of cognitive behaviour therapy for chronic fatigue syndrome. Psychotherapy and Psychosomatics 2010; 79(4): 249–56.
91. WhitePD, GoldsmithKA, JohnsonAL, PottsL, WalwynR, DeCesareJCet al. and on behalf of the PACE trial management group. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and socialist medical care for chronic fatigue syndrome (PACE): a randomised trial. The Lancet 2011; 377: 823–36.
92. KnoopH, PrinsJ, Moss-MorrisR, BleijenbergG. The central role of perception in the perpetuation of chronic fatigue syndrome. Journal of Psychosomatic Research 2010; 68(5): 489–94.
93. ChalderT, GodfreyE, RidsdaleL, KingM, WesselyS. Predictors of outcome in a fatigued population in primary care following a randomized controlled trial. Psychological Medicine 2003; 33(2): 283–7.
94. GodfreyE, ChaiderT, RidsdaleL, SeedP, OgdenJ. Investigating the ‘active ingredients’ of cognitive behaviour therapy and counselling for patients with chronic fatigue in primary care: developing a new process measure to assess treatment fidelity and predict outcome. British Journal of Clinical Psychology 2007; 46: 253–72.
95. WiborgJF, KnoopH, StulemeijerM, PrinsJB, BleijenbergG. How does cognitive behaviour therapy reduce fatigue in patients with chronic fatigue syndrome? The role of physical activity. Psychological Medicine 2010; 40(8): 1281–7.
96. FulcherKY, WhitePD. Strength and physiological response to exercise in patients with chronic fatigue syndrome. Journal of Neurology Neurosurgery and Psychiatry 2000; 69(3): 302–7.
97. Moss-MorrisR, SharonC, TobinR, BaldiJC. A randomized controlled graded exercise trial for chronic fatigue syndrome: Outcomes and mechanisms of change. Journal of Health Psychology 2005; 10(2): 245–59.
98. BentallRP, PowellP, NyeFJ, EdwardsRHT. Predictors of response to treatment for chronic fatigue syndrome. British Journal of Psychiatry 2002; 181: 248–52.
99. de LangeFP, KoersA, KalkmanJS, BleijenbergG, HagoortP, van der MeerJWMet al. Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. Brain 2008; 131: 2172–80.
100. RobertsADL, PapadopoulosAS, WesselyS, ChalderT, CleareAJ. Salivary cortisol output before and after cognitive behavioural therapy for chronic fatigue syndrome. Journal of Affective Disorders 2009; 115(1–2): 280–6.
101. TabasG, BeavesM, WangJ, FridayP, MardiniH, ArnoldG. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. American Journal of Gastroenterology 2004; 99(5): 914–20.
102. TackJ, BroekaertD, FischlerB, OudenhoveLV, GeversAM, JanssensJ.A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55(8): 1095–103.
103. DrossmanDA, TonerBB, WhiteheadWE, DiamantNE, DaltonCB, DuncanSet al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125(1): 19–31.
104. VijJC, JilohaRC, KumarN. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Indian Journal of Psychiatry 1991; 33: 243–6.
105. RobinsonA, LeeV, KennedyA, MiddletonL, RogersA, ThompsonDGet al. A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome. Gut 2006; 55(5): 643–8.
106. KennedyT, JonesR, DarnleyS, SeedP, WesselyS, ChalderTet al. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. British Medical Journal 2005; 331(7514): 435.
107. CreedF, FernandesL, GuthrieE, PalmerS, RatcliffeJ, ReadNet al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124(2): 303–17.
108. HarrisLR, RobertsL. Treatments for irritable bowel syndrome: patients’ attitudes and acceptability. BMC Complementary and Alternative Medicine 2008; 8: 65.
109. HäuserW, ThiemeK, TurkDC. Guidelines on the management of fibromyalgia syndrome – a systematic review. European Journal of Pain 2010; 14(1): 5–10.
110. MeasePJ, ChoyEH. Pharmacotherapy of fibromyalgia. Rheumatic Disease Clinics of North America 2009; 35(2): 359–72.
111. BernardyK, FuberN, KollnerV, HauserW. Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome – a systematic review and metaanalysis of randomized controlled trials. Journal of Rheumatology 2010; 37: 1991–2005.
112. van KoulilS, EfftingM, KraaimaatFW, van LankveldW, van HelmondT, CatsHet al. Cognitive-behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions. Annals of the Rheumatic Diseases 2007; 66(5): 571–81.
113. ThiemeK, Gromnica-IhleE, FlorH. Operant behavioral treatment of fibromyalgia: a controlled study. Arthritis and Rheumatism 2003; 49(3): 314–20.
114. HauserW, KloseP, LanghorstJ, MoradiB, SteinbachM, SchiltenwolfMet al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Research and Therapy 2010; 12(3): R79.
115. ArnoldLM, RosenA, PritchettYL, D’SouzaDN, GoldsteinDJ, IyengarSet al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119(1–3): 5–15.
116. ArnoldLM, LuYL, CroffordLJ, WohlreichM, DetkeMJ, IyengarSet al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism 2004; 50(9): 2974–84.
117. RussellIJ, MeasePJ, SmithTR, KajdaszDK, WohlreichMM, DetkeMJet al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008; 136(3): 432–44.
118. RooksDS, GautamS, RomelingM, CrossML, StratigakisD, EvansBet al. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Archives of Internal Medicine 2007; 167(20): 2192–200.
119. KroenkeK, BairMJ, DamushTM, WuJW, HokeS, SutherlandJet al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain a randomized controlled trial. Journal of the American Medical Association 2009; 301(20): 2099–110.
120. McCroneP, KnappM, KennedyT, SeedP, JonesR, DarnleySet al. Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. European Journal of Gastroenterology and Hepatology 2008; 20(4): 255–63.
121. SeverensJL, PrinsJB, van der WiltGJ, van der MeerJWM, BleijenbergG. Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome. QJM – Monthly Journal of the Association of Physicians 2004; 97(3): 153–61.
122. McCroneP, RidsdaleL, DarbishireL, SeedP, McCroneP, RidsdaleLet al. Cost-effectiveness of cognitive behavioural therapy, graded exercise and usual care for patients with chronic fatigue in primary care. Psychological Medicine 2004; 34(6): 991–9.
123. GoossensME, Rutten-van MolkenMP, LeidlRM, BosSG, VlaeyenJW, Teeken-GrubenNJ. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. II. Economic evaluation. Journal of Rheumatology 1996; 23(7): 1246–54.
124. TummersM, KnoopH, BleijenbergG. Effectiveness of stepped care for chronic fatigue syndrome: a randomized noninferiority trial. Journal of Consulting and Clinical Psychology 2010; 78(5): 724–31.
125. CreedF, TomensonB, GuthrieE, RatcliffeJ, FernandesL, ReadNet al. The relationship between somatisation and outcome in patients with severe irritable bowel syndrome. Journal of Psychosomatic Research 2008; 64: 613–20.